Receptor activator of nuclear factor kappa-B ligand signaling pathway modulator (RANKL signaling pathway modulator)

“RANKL signaling pathway modulators” refers not to a single molecular target but to agents that modulate the signaling of receptor activator of nuclear factor kappa-B ligand (RANKL). RANKL, also known as TNFSF11, is a cytokine of the tumor necrosis factor (TNF) family that binds to its receptor RANK, activating downstream signaling that is essential for osteoclast development, function, and survival[5][7][3][9]. The RANKL–RANK–OPG axis is crucial for bone metabolism, regulating bone resorption and remodeling, but also plays important roles in immune regulation and cancer biology[3][1][4][8]. Therapeutic modulation of this pathway—primarily inhibition using monoclonal antibodies such as denosumab—has proven efficacious in diseases with pathological bone loss (such as osteoporosis, bone metastasis, and multiple myeloma)[7][1][3]. Safety concerns with pharmacologic RANKL inhibition include hypocalcemia, increased infection risk, and osteonecrosis of the jaw[7]. Drugs that act as RANKL signaling pathway modulators act through directly targeting RANKL to prevent its interaction with RANK on osteoclast precursors, thereby preventing bone resorption[7][3].

Other names

Receptor activator of nuclear factor kappa-B ligand pathway modulatorRANKL modulatorTNFSF11 pathway modulatorOsteoprotegerin ligand (OPGL) pathway modulatorOsteoclast differentiation factor (ODF) pathway modulator

Inhibition of RANKL–RANK interaction (e.g., by anti-RANKL monoclonal antibodies) Decoy receptor interference (e.g., OPG blocks RANKL binding to RANK)